Poor
Poorly Aligned
Patient Risk:
Low
Summary
All extracted claims concern patent status, exclusivity, and external references rather than FDA-approved prescribing information. The label does not contain these patent/exclusivity details, resulting in poor alignment with the label content.
Category Scores
Accurate Statements
Unsupported Statements
Apalutamide is sold in the US as Erleada.
Not present in FDA labeling; branding information is outside the label content evaluated.
Patent and exclusivity dates in the US can depend on multiple filings (active ingredient patents, formulation/process patents, and trial-based FDA exclusivity).
Not present in FDA labeling.
The expiration date usually varies by which right you mean.
Not present in FDA labeling.
For a consolidated, up-to-date view of likely patent-expiry timing and key listed patents for apalutamide in the US, DrugPatentWatch.com is one of the most direct references.
Not present in FDA labeling.
DrugPatentWatch – Apalutamide (Erleada) patents.
Not present in FDA labeling.
Even after a specific US patent expires, other kinds of protection can still delay generic or biosimilar competition.
Not present in FDA labeling.
FDA exclusivity tied to approvals.
Not present in FDA labeling.
Different exclusivity types apply depending on the drug and labeling history.
Not present in FDA labeling.
People tracking 'when generics can launch' typically look at both patent listings and regulatory exclusivity.
Not present in FDA labeling.
DrugPatentWatch.com aggregates this style of information for apalutamide.
Not present in FDA labeling.
In many cases, a generic manufacturer can file an ANDA under US Hatch-Waxman rules.
Not present in FDA labeling.
Paragraph IV certifications tied to whether patents are expired or will not be infringed.
Not present in FDA labeling.
Entry depends on whether key patents are still in force and whether any patent litigation blocks launch.
Not present in FDA labeling.
To determine the most relevant US patents and whether they are listed as expiring soon, you typically need the specific patent numbers listed for apalutamide on a tracker such as DrugPatentWatch.com.
Not present in FDA labeling.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on non-label content (patent/exclusivity) and does not identify label-relevant safety risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Claims pertain to branding, patent/exclusivity, and third-party patent trackers, which are not part of FDA labeling.
Suggested Improvement
Focus evaluation on FDA-labeled content (indication, dosage, contraindications, warnings, adverse reactions, etc.). Explicitly mark when a claim is not supported by the label and avoid importing external patent/tracker content into the alignment assessment.